{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:09:57Z","timestamp":1789103397042,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In end-stage kidney disease, patients may undergo parathyroidectomy if secondary hyperparathyroidism cannot be managed medically. This study was designed to estimate the parathyroidectomy rate in the United States (US) and to quantify changes in costs and other outcomes after parathyroidectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective observational cohort study using US Renal Data System data for 2015\u20132018. Parathyroidectomy rates were estimated for adult hemodialysis and peritoneal dialysis patients alive at the beginning of 2016, 2017, and 2018 who were followed for a year or until parathyroidectomy, death, or transplant. Incremental differences in economic and clinical outcomes were compared before and after parathyroidectomy in adult hemodialysis and peritoneal dialysis patients who received a parathyroidectomy in 2016 and 2017.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The rate of parathyroidectomy per 1,000\nperson-years decreased from 6.5 (95% CI 6.2-6.8) in 2016 to 5.3 (95% CI\n5.0-5.6) in 2018. The incremental\nincrease in 12-month cost after versus before parathyroidectomy was $25,314\n(95% CI $23,777-$27,078). By the second\nmonth after parathyroidectomy, 58% of patients had a corrected calcium level\n&lt; 8.5 mg\/dL. In the year after\nparathyroidectomy (versus before), hospitalizations increased by 1.4 per\nperson-year (95% CI 1.3-1.5), hospital days increased by 12.1 per person-year\n(95% CI 11.2-13.0), dialysis visits decreased by 5.2 per person-year (95% CI\n4.4-5.9), and office visits declined by 1.3 per person-year (95% CI\n1.0-1.5). The incremental rate per 1,000\nperson years for hematoma\/bleed was 224.4 (95% CI 152.5-303.1), for vocal cord\nparalysis was 124.6 (95% CI 59.1-232.1), and for seroma was 27.4 (95% CI\n0.4-59.0).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Parathyroidectomy was a relatively uncommon event in the hemodialysis and peritoneal dialysis populations. The incremental cost of parathyroidectomy was mostly attributable to the cost of the parathyroidectomy hospitalization. Hypocalcemia occurred in over half of patients, and calcium and phosphate levels were reduced. Clinicians, payers, and patients should understand the potential clinical and economic outcomes when considering parathyroidectomy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02848-x","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:02:23Z","timestamp":1655845343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016\u20132018"],"prefix":"10.1186","volume":"23","author":[{"given":"Mark D","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Duryea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"1","key":"2848_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KI Supplements","year":"2017","unstructured":"Supplements KI. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"2848_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7326\/M17-2640","volume":"168","author":"M Ketteler","year":"2018","unstructured":"Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med. 2018;168(6):422. https:\/\/doi.org\/10.7326\/M17-2640.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2848_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/CJN.10390917","volume":"13","author":"WL Lau","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952\u201361. https:\/\/doi.org\/10.2215\/CJN.10390917.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2848_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.2215\/CJN.10370915","volume":"11","author":"SM Kim","year":"2016","unstructured":"Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the united states. Clin J Am Soc Nephrol. 2016;11(7):1260\u20137. https:\/\/doi.org\/10.2215\/CJN.10370915.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2848_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/0194599817721154","volume":"157","author":"R Ferrandino","year":"2017","unstructured":"Ferrandino R, Roof S, Ma Y, et al. Unplanned 30-day readmissions after parathyroidectomy in patients with chronic kidney disease: a nationwide analysis. Otolaryngol-Head Neck Surg. 2017;157(6):955\u201365. https:\/\/doi.org\/10.1177\/0194599817721154.","journal-title":"Otolaryngol-Head Neck Surg"},{"issue":"1","key":"2848_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-13-248","volume":"13","author":"V Belozeroff","year":"2013","unstructured":"Belozeroff V, Cooper K, Hess G, Chang CL. Healthcare use and costs before and after parathyroidectomy in patients on dialysis. BMC Health Serv Res. 2013;13(1):1. https:\/\/doi.org\/10.1186\/1472-6963-13-248.","journal-title":"BMC Health Serv Res"},{"key":"2848_CR7","unstructured":"United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States.\u00a0Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020."},{"key":"2848_CR8","unstructured":"United States Renal Data System (USRDS). Accessed 27 Jan 2021. https:\/\/www.usrds.org"},{"issue":"11","key":"2848_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"7","key":"2848_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1210\/jc.2017-00255","volume":"102","author":"M Papaleontiou","year":"2017","unstructured":"Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab. 2017;102(7):2543\u201351. https:\/\/doi.org\/10.1210\/jc.2017-00255.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2848_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ekir.2020.11.023","volume":"6","author":"GK Steinl","year":"2021","unstructured":"Steinl GK, Kuo JH. Surgical management of secondary hyperparathyroidism. Kidney Int Rep. 2021;6(2):254\u201364. https:\/\/doi.org\/10.1016\/j.ekir.2020.11.023.","journal-title":"Kidney Int Rep"},{"key":"2848_CR12","doi-asserted-by":"publisher","unstructured":"Liu J, Huang Q, Yang M, Huang L, Zhang L. Risk factors predicting severe hypocalcemia after total parathyroidectomy without autotransplantation in patients with secondary hyperparathyroidism. J Int Medl Res. 2020;48(1). https:\/\/doi.org\/10.1177\/0300060519897505.","DOI":"10.1177\/0300060519897505"},{"key":"2848_CR13","unstructured":"Breslow NE, Day NE. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1\u2013406. PMID: 3329634. https:\/\/pubmed.ncbi.nlm.nih.gov\/3329634\/."},{"issue":"5","key":"2848_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jval.2012.03.1388","volume":"15","author":"RIRI Griffiths","year":"2012","unstructured":"Griffiths RIRI, Gleeson MLML, Danese MDMD, O\u2019Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-medicare. Value Health. 2012;15(5):656\u201363. https:\/\/doi.org\/10.1016\/j.jval.2012.03.1388.","journal-title":"Value Health"},{"key":"2848_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/biostatistics\/1.1.35","volume":"1","author":"DY Lin","year":"2000","unstructured":"Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1:35\u201347. https:\/\/doi.org\/10.1093\/biostatistics\/1.1.35.","journal-title":"Biostatistics"},{"issue":"1","key":"2848_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12911-019-0837-5","volume":"19","author":"MD Danese","year":"2019","unstructured":"Danese MD, Halperin M, Duryea J, Duryea R. The generalized data model for clinical research. BMC Med Inform Decis Mak. 2019;19(1):1\u201313. https:\/\/doi.org\/10.1186\/s12911-019-0837-5.","journal-title":"BMC Med Inform Decis Mak"},{"key":"2848_CR17","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021.\u00a0 https:\/\/www.R-project.org\/."},{"issue":"5","key":"2848_CR18","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","volume":"66","author":"B Kestenbaum","year":"2004","unstructured":"Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66(5):2010\u20136. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00972.x.","journal-title":"Kidney Int"},{"issue":"10","key":"2848_CR19","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/ndt\/gfaa054","volume":"35","author":"MB Lopes","year":"2020","unstructured":"Lopes MB, Karaboyas A, Bieber B, et al. Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. Nephrol Dial Transplant. 2020;35(10):1794\u2013801. https:\/\/doi.org\/10.1093\/ndt\/gfaa054.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02848-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:02:28Z","timestamp":1655845348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02848-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02848-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed by the Advarra Institutional Review Board (IRB) and received an exemption determination on April 2, 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the time this research was conducted Jennifer Duryea was an employee of Outcomes Insights, Inc. Kathleen Fox was a contract worker for Amgen but received no stock or stock options. Robert Rubin was a consultant to Amgen. Pooja Desai was an Amgen employee with Amgen stock. Mark Danese was an employee and owner of Outcomes Insights, Inc., the organization funded to conduct this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}